<DOC>
	<DOCNO>NCT01507038</DOCNO>
	<brief_summary>The objective study ass safety , efficacy pharmacokinetic YH14617 weekly biweekly injection patient type 2 Diabetes Mellitus investigate optimal recommend dosage . Study period 20 week include 12 week treatment period 8weeks follow-up period without treatment .</brief_summary>
	<brief_title>Safety Efficacy YH14617 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>Have sign write informed consent voluntary , prior procedure Volunteers age 20 year 75 year Have diagnose type 2 diabetes least 3 month prior study Have body mass index ( BMI ) &gt; 23kg/m2 history stable body weight 3 month prior first administration ( vary &gt; 5 % weight ) Have treat stable dose regimen Metformin &gt; 1500mg/day maximum tolerant dose least 3 month prior first administration Have HbA1c 7 % 10 % inclusive Have treat insulin , sulfonylurea , thiazolidinedione class hypoglycemic drug , exenatide GLP1 receptor agonist , DPP4inhibitor , glucocorticoid drug promote weight loss within 3 month prior first administration Have acute disease , untreated disease diabetic complication need additional treatment Have severe renal disorder ( serum creatinine concentration &gt; 1.5 time normal upper limit ) liver disorder ( liver enzyme &gt; 2 time normal upper limit ) Have blood pressure &gt; 160/100mmHg Have hospitalize due cardiac disorder ( angina , cardiac infarction , heart failure etc . ) within 1 year prior first administration Have history critical disease within 1 year prior first administration Have untreated malignant tumor history significant malignant tumor within 5 year prior first administration Have fast plasma glucose ( FPG ) &gt; 250mg/dl random glucose level &gt; 350mg/dl Have 1 history severe hypoglycemia need others help within 3 month prior first administration Have know allergy hypersensitivity drug Pregnant woman , nurse mother subject agree assign contraception study Participated clinical trial within 30 day prior first administration Subject judge ineligible principal investigator subinvestigator accord various reason</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>YH14617</keyword>
	<keyword>Exenatide</keyword>
	<keyword>Yuhan</keyword>
</DOC>